Haleon plc (NYSE: HLN) Stock Competitors & Peer Comparison

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TAK has a market cap of 63.9B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TAK trades at $20.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TAK's P/E ratio is 14.44. In terms of profitability, HLN's ROE is +0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, HLN is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TAK's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TEVA has a market cap of 47.6B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TEVA trades at $40.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TEVA's P/E ratio is 13.95. In terms of profitability, HLN's ROE is +0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, HLN is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TEVA's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ZTS has a market cap of 33.1B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ZTS trades at $80.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ZTS's P/E ratio is 12.17. In terms of profitability, HLN's ROE is +0.10%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, HLN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ZTS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while VTRS trades at $18.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas VTRS's P/E ratio is 7.40. In terms of profitability, HLN's ROE is +0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, HLN is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check VTRS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HLN's ROE is +0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HLN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for HLN.Check ITCI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HLN's ROE is +0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HLN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for HLN.Check CTLT's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ELAN has a market cap of 11.3B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ELAN trades at $22.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ELAN's P/E ratio is 21.42. In terms of profitability, HLN's ROE is +0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, HLN is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ELAN's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, RDY has a market cap of 11B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while RDY trades at $13.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas RDY's P/E ratio is 28.23. In terms of profitability, HLN's ROE is +0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, HLN is similarly volatile compared to RDY. This indicates similar risk in terms of short-term price fluctuations for HLN.Check RDY's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ALKS trades at $44.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ALKS's P/E ratio is 46.43. In terms of profitability, HLN's ROE is +0.10%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, HLN is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ALKS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while LNTH trades at $100.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas LNTH's P/E ratio is 16.87. In terms of profitability, HLN's ROE is +0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HLN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for HLN.Check LNTH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AMRX has a market cap of 6.3B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AMRX trades at $19.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AMRX's P/E ratio is 22.04. In terms of profitability, HLN's ROE is +0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, HLN is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AMRX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, RGC has a market cap of 5.2B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while RGC trades at $10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas RGC's P/E ratio is -1045.00. In terms of profitability, HLN's ROE is +0.10%, compared to RGC's ROE of -1.61%. Regarding short-term risk, HLN is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check RGC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while INDV trades at $34.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas INDV's P/E ratio is 9.53. In terms of profitability, HLN's ROE is +0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, HLN is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for HLN.Check INDV's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while HCM trades at $14.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas HCM's P/E ratio is 142.55. In terms of profitability, HLN's ROE is +0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, HLN is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for HLN.Check HCM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ALVOW trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, HLN's ROE is +0.10%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, HLN is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for HLN.Check ALVOW's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SUPN trades at $41.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SUPN's P/E ratio is 13.47. In terms of profitability, HLN's ROE is +0.10%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, HLN is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for HLN.Check SUPN's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while BHC trades at $6.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas BHC's P/E ratio is 1.64. In terms of profitability, HLN's ROE is +0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, HLN is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check BHC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PRGO trades at $16.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PRGO's P/E ratio is 6.47. In terms of profitability, HLN's ROE is +0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, HLN is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check PRGO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HLN's ROE is +0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HLN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for HLN.Check DCPH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HLN's ROE is +0.10%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, HLN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for HLN.Check AVDL's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, HLN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for HLN.Check EMBCV's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TRLV has a market cap of 1.8B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TRLV trades at $10.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TRLV's P/E ratio is -4.38. In terms of profitability, HLN's ROE is +0.10%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, HLN is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TRLV's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ALVO trades at $5.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ALVO's P/E ratio is -8.68. In terms of profitability, HLN's ROE is +0.10%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, HLN is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ALVO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HLN's ROE is +0.10%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, HLN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for HLN.Check DVAX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ANIP trades at $72.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ANIP's P/E ratio is 8.84. In terms of profitability, HLN's ROE is +0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, HLN is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ANIP's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TARO's P/E ratio is 30.05. In terms of profitability, HLN's ROE is +0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HLN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for HLN.Check TARO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PAHC trades at $38.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PAHC's P/E ratio is 13.24. In terms of profitability, HLN's ROE is +0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HLN is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check PAHC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PCRX trades at $36.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PCRX's P/E ratio is 13.99. In terms of profitability, HLN's ROE is +0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, HLN is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for HLN.Check PCRX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ETON trades at $50.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ETON's P/E ratio is 132.08. In terms of profitability, HLN's ROE is +0.10%, compared to ETON's ROE of +0.40%. Regarding short-term risk, HLN is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ETON's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CRON trades at $3.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CRON's P/E ratio is 16.79. In terms of profitability, HLN's ROE is +0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CRON's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AMPH trades at $25.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AMPH's P/E ratio is 8.85. In terms of profitability, HLN's ROE is +0.10%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HLN is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AMPH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while HROW trades at $28.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas HROW's P/E ratio is -28.35. In terms of profitability, HLN's ROE is +0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, HLN is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for HLN.Check HROW's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HLN's ROE is +0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HLN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for HLN.Check PETQ's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, COLL has a market cap of 756.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while COLL trades at $23.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas COLL's P/E ratio is 2.91. In terms of profitability, HLN's ROE is +0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, HLN is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for HLN.Check COLL's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, IRWD has a market cap of 599.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while IRWD trades at $3.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas IRWD's P/E ratio is 4.65. In terms of profitability, HLN's ROE is +0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, HLN is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for HLN.Check IRWD's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HLN's ROE is +0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HLN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for HLN.Check BDSI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, EVO has a market cap of 525.7M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while EVO trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas EVO's P/E ratio is -2.09. In terms of profitability, HLN's ROE is +0.10%, compared to EVO's ROE of -0.27%. Regarding short-term risk, HLN is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check EVO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AQST has a market cap of 508.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AQST trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AQST's P/E ratio is -6.23. In terms of profitability, HLN's ROE is +0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, HLN is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AQST's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, EOLS has a market cap of 486.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while EOLS trades at $7.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas EOLS's P/E ratio is -23.34. In terms of profitability, HLN's ROE is +0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, HLN is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check EOLS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, KMDA has a market cap of 452.9M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while KMDA trades at $7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas KMDA's P/E ratio is 20.66. In terms of profitability, HLN's ROE is +0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HLN is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for HLN.Check KMDA's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TKNO has a market cap of 396.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TKNO trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TKNO's P/E ratio is -23.84. In terms of profitability, HLN's ROE is +0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, HLN is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TKNO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TLRY trades at $3.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TLRY's P/E ratio is -2.16. In terms of profitability, HLN's ROE is +0.10%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, HLN is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TLRY's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, EBS has a market cap of 322.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while EBS trades at $6.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas EBS's P/E ratio is 4.37. In terms of profitability, HLN's ROE is +0.10%, compared to EBS's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check EBS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CGC has a market cap of 304.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CGC trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CGC's P/E ratio is -1.61. In terms of profitability, HLN's ROE is +0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, HLN is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CGC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HLN's ROE is +0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HLN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for HLN.Check ALIM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HLN's ROE is +0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, HLN is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check LNDC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ACB trades at $3.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ACB's P/E ratio is -2.87. In terms of profitability, HLN's ROE is +0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ACB's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, LFCR has a market cap of 241.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while LFCR trades at $6.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas LFCR's P/E ratio is -5.02. In terms of profitability, HLN's ROE is +0.10%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, HLN is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for HLN.Check LFCR's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HLN's ROE is +0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HLN is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TYHT's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SIGA has a market cap of 226.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SIGA trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SIGA's P/E ratio is 11.67. In terms of profitability, HLN's ROE is +0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, HLN is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for HLN.Check SIGA's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, GLAS has a market cap of 182M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while GLAS trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas GLAS's P/E ratio is -4.15. In terms of profitability, HLN's ROE is +0.10%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, HLN is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check GLAS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas REPH's P/E ratio is -8.04. In terms of profitability, HLN's ROE is +0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HLN is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for HLN.Check REPH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas THTX's P/E ratio is -28.83. In terms of profitability, HLN's ROE is +0.10%, compared to THTX's ROE of +0.36%. Regarding short-term risk, HLN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for HLN.Check THTX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ASRT's P/E ratio is -7.10. In terms of profitability, HLN's ROE is +0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HLN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for HLN.Check ASRT's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, DERM has a market cap of 147.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while DERM trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas DERM's P/E ratio is -23.73. In terms of profitability, HLN's ROE is +0.10%, compared to DERM's ROE of -0.20%. Regarding short-term risk, HLN is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for HLN.Check DERM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CRDL has a market cap of 138.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CRDL trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CRDL's P/E ratio is -4.58. In terms of profitability, HLN's ROE is +0.10%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, HLN is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CRDL's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, OGI has a market cap of 132.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while OGI trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas OGI's P/E ratio is 2.10. In terms of profitability, HLN's ROE is +0.10%, compared to OGI's ROE of +0.21%. Regarding short-term risk, HLN is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for HLN.Check OGI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ORGO trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ORGO's P/E ratio is 34.00. In terms of profitability, HLN's ROE is +0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, HLN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ORGO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CPIX trades at $7.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CPIX's P/E ratio is -19.90. In terms of profitability, HLN's ROE is +0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, HLN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CPIX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HLN's ROE is +0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HLN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for HLN.Check SCTL's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, BGM has a market cap of 108.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while BGM trades at $8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas BGM's P/E ratio is -1.78. In terms of profitability, HLN's ROE is +0.10%, compared to BGM's ROE of -0.05%. Regarding short-term risk, HLN is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for HLN.Check BGM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PROC's P/E ratio is 1.53. In terms of profitability, HLN's ROE is +0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HLN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for HLN.Check PROC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HLN's ROE is +0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, HLN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for HLN.Check OPTN's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HLN's ROE is +0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, HLN is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ZOM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HLN's ROE is +0.10%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, HLN is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for HLN.Check GRVI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ZYBT trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, HLN's ROE is +0.10%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, HLN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ZYBT's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HLN's ROE is +0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HLN is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ZYNE's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HLN's ROE is +0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HLN is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check SSIC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HLN's ROE is +0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check VLNS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HLN's ROE is +0.10%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, HLN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for HLN.Check DRRX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TLPH has a market cap of 55.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TLPH trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TLPH's P/E ratio is -3.96. In terms of profitability, HLN's ROE is +0.10%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, HLN is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TLPH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, INCR has a market cap of 53.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while INCR trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas INCR's P/E ratio is -4.76. In terms of profitability, HLN's ROE is +0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HLN is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for HLN.Check INCR's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HLN's ROE is +0.10%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, HLN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for HLN.Check JUPW's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas QLI's P/E ratio is -4.92. In terms of profitability, HLN's ROE is +0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HLN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for HLN.Check QLI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HLN's ROE is +0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HLN is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for HLN.Check HEXO's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CPHI has a market cap of 31.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CPHI trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CPHI's P/E ratio is -1.68. In terms of profitability, HLN's ROE is +0.10%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, HLN is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CPHI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, RMTI has a market cap of 29.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while RMTI trades at $7.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas RMTI's P/E ratio is -5.40. In terms of profitability, HLN's ROE is +0.10%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, HLN is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for HLN.Check RMTI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HLN's ROE is +0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HLN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for HLN.Check CYTH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SHPH has a market cap of 23.4M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SHPH trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SHPH's P/E ratio is -0.23. In terms of profitability, HLN's ROE is +0.10%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, HLN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for HLN.Check SHPH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, TXMD has a market cap of 22.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while TXMD trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas TXMD's P/E ratio is 97.30. In terms of profitability, HLN's ROE is +0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, HLN is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for HLN.Check TXMD's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AYTU has a market cap of 21.8M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AYTU trades at $2.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AYTU's P/E ratio is -1.70. In terms of profitability, HLN's ROE is +0.10%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, HLN is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AYTU's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, OPTH has a market cap of 19.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while OPTH trades at $3.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas OPTH's P/E ratio is -2.15. In terms of profitability, HLN's ROE is +0.10%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, HLN is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for HLN.Check OPTH's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HLN's ROE is +0.10%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, HLN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for HLN.Check EVOK's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HLN's ROE is +0.10%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, HLN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ACRX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HLN's ROE is +0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HLN is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AGRX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, CABR has a market cap of 9.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while CABR trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas CABR's P/E ratio is -1.36. In terms of profitability, HLN's ROE is +0.10%, compared to CABR's ROE of -3.86%. Regarding short-term risk, HLN is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for HLN.Check CABR's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HLN's ROE is +0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, HLN is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for HLN.Check NLTX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas LCI's P/E ratio is -0.04. In terms of profitability, HLN's ROE is +0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HLN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for HLN.Check LCI's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, INM has a market cap of 7.4M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while INM trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas INM's P/E ratio is -0.44. In terms of profitability, HLN's ROE is +0.10%, compared to INM's ROE of -1.35%. Regarding short-term risk, HLN is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for HLN.Check INM's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HLN's ROE is +0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HLN is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for HLN.Check ADMP's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, SNOA has a market cap of 5.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while SNOA trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas SNOA's P/E ratio is -1.05. In terms of profitability, HLN's ROE is +0.10%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, HLN is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for HLN.Check SNOA's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas MNK's P/E ratio is -0.44. In terms of profitability, HLN's ROE is +0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for HLN.Check MNK's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, YCBD has a market cap of 4.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while YCBD trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas YCBD's P/E ratio is -0.95. In terms of profitability, HLN's ROE is +0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, HLN is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for HLN.Check YCBD's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HLN's ROE is +0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, HLN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check FLGC's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, GELS has a market cap of 4.1M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while GELS trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas GELS's P/E ratio is -1.02. In terms of profitability, HLN's ROE is +0.10%, compared to GELS's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for HLN.Check GELS's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, AKAN has a market cap of 2.6M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while AKAN trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas AKAN's P/E ratio is -0.02. In terms of profitability, HLN's ROE is +0.10%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, HLN is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for HLN.Check AKAN's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HLN's ROE is +0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HLN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for HLN.Check PLXP's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HLN's ROE is +0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HLN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for HLN.Check ATNX's competition here

Haleon plc (NYSE: HLN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HLN stands at 44.7B. In comparison, UPC has a market cap of 2.2M. Regarding current trading prices, HLN is priced at $10.17 on the NYSE, while UPC trades at $3.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HLN currently has a P/E ratio of 20.82, whereas UPC's P/E ratio is -0.44. In terms of profitability, HLN's ROE is +0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, HLN is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for HLN.Check UPC's competition here